Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.

Authors:
Liu X; Zhang R; Li R; Wu Q; Pan C and 4 more

Journal:
Antimicrob Agents Chemother

Publication Year: 2023

DOI:
10.1128/aac.01075-23

PMCID:
PMC10720486

PMID:
37971243

Journal Information

Full Title: Antimicrob Agents Chemother

Abbreviation: Antimicrob Agents Chemother

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Anti-Infective Agents

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Shuwen Yu and Benjie Wang have served as speakers for Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Qiong Wu, Chao Pan, Xiangqing Yu, and Yuhui Liu are the employees of Jiangsu Hansoh Pharmaceutical Group Co., Ltd, the sponsor of the study, at the time of this study. The remaining authors declare no conflict of interest."

Evidence found in paper:

"This study was funded by the Jiangsu Hansoh Pharmaceutical Group Co., Ltd."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025